Tumor progression could be delayed with AvastinA retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance has suggested that the use of Avastin to treat a subgroup of recurrent Grade 3 brain tumors is safe and effective at the same time.

Bevacizumab (also known as Avastin) emerges out as a potential therapy for gliomas, according to Marc Chamberlain, who is director of the Neuro-oncology Program at the SCCA and a professor of neurology and neurological surgery at the University of Washington School of Medicine and author of the study.

It is worthwhile to note here that Avastin is the first-approved therapy to inhibit angiogenesis, which is the process wherein new blood vessels are developed and important nutrients are transported to a tumor.

Comments

comments